Advocates have long argued that marijuana legalization is a superior alternative to criminalization. But while that sentiment prevails with the public and a growing number of lammakers, a leading drug policy reform group says it’s nonetheless important to recognize and address potential public health impacts of consumer trends in state-regulated markets—including the rise of high-potency THC products.
Prohibitionists have been quick to seize upon reports of adverse health incidents associated with products engineered to maximize THC, whether it’s naturally produced delta-9 THC in marijuana, synthetically manufactured delta-8 THC in hemp or any of the numerous other iterations of the intoxicating cannabinoid.
But rather than revert to banning such products outright, officials should prioritize targeted regulations to balance public health and consumer choice, the pro-legalization Drug Policy Alliance (DPA) said in a new report titled “High-THC Marijuana: Protecting Public Health In A Changing Market.”
“As product potency rises, so do important public health questions about safety, youth access, and consumer transparency,” it says, adding that DPA’s position is that “legalization must be paired with thoughtful, evidence-based regulation that protects health, enhances safety, and reduces harm.”
The organization isn’t necessarily arguing that high-THC cannabis products present an imminent public health threat, pointing
Read full article on Marijuana Moment
